trending Market Intelligence /marketintelligence/en/news-insights/trending/enzkp2pdpbomafd9rwt8dw2 content esgSubNav
In This List

Insulet's insulin management system gets FDA approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Insulet's insulin management system gets FDA approval

Insulet Corp. said the U.S. Food and Drug Administration granted 510(k) clearance to its Omnipod Dash insulin management system.

The system includes a handheld personal diabetes manager that is designed for use with a blood glucose meter and certain mobile applications.

The approval allows Insulet to commercialize the product in the U.S., with full market release expected to start early 2019.

Billerica, Mass.-based Insulet is a medical device company that develops and sells insulin delivery systems for people with insulin-dependent diabetes.